- $1.02bn
- $1.28bn
- $388.54m
- 76
- 31
- 50
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 171.07 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.68 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 92.12 | ||
| Price to Sales | 2.62 | ||
| EV to EBITDA | 21.58 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.87% | ||
| Return on Equity | -4.78% | ||
| Operating Margin | 9.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 253.23 | 298.84 | 313.79 | 354 | 388.54 | 423.64 | 469.25 | 7.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +2264.71 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons’ challenges in treating patients with aortic diseases. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.
Directors
- James Mackin CHM (54)
- D. Ashley Lee CFO (56)
- Jean Holloway SVP (63)
- John Davis SVP (56)
- Amy Horton CAO (50)
- Dennis Maier VOP (47)
- Matthew Getz VPR (52)
- F. Peter Barthold VPR (56)
- Scott Capps VPR (54)
- Thomas Ackerman IND (66)
- Daniel Bevevino IND (61)
- Marna Borgstrom IND (67)
- James Bullock IND (64)
- Jeffrey Burbank IND (58)
- Jon Salveson IND (56)
- Anthony Semedo IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 2022
- Public Since
- February 12th, 1993
- No. of Shareholders
- 157
- No. of Employees
- 1,600
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 42,689,303
- Address
- 1655 Roberts Boulevard N W, KENNESAW, 30144
- Web
- https://artivion.com/
- Phone
- +1 7704193355
- Contact
- Brian Johnston
- Auditors
- Ernst & Young LLP
Upcoming Events for AORT
Q1 2025 Artivion Inc Earnings Call
Artivion Inc Annual Shareholders Meeting
Artivion Inc Annual Shareholders Meeting
Q2 2025 Artivion Inc Earnings Release
Similar to AORT
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Avanos Medical
New York Stock Exchange
Avantor
New York Stock Exchange
FAQ
What is the Artivion share price?
As of Today at 19:20 UTC, shares in Artivion are trading at $23.84. This share price information is delayed by 15 minutes.
How has the Artivion share price performed this year?
Shares in Artivion last closed at $23.84 and the price had moved by +17.61% over the past 365 days. In terms of relative price strength the Artivion share price has outperformed the S&P500 Index by +8.56% over the past year.
What are the analyst and broker recommendations for Artivion?
The overall consensus recommendation for Artivion is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Artivion dividend yield?
Artivion does not currently pay a dividend.
Does Artivion pay a dividend?
Artivion does not currently pay a dividend.
When does Artivion next pay dividends?
Artivion does not currently pay a dividend.
How do I buy Artivion shares?
To buy shares in Artivion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Artivion?
As of the previous close price of $23.84, shares in Artivion had a market capitalisation of $1.02bn.
Where are Artivion shares listed?
Here are the trading details for Artivion:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: AORT
What kind of share is Artivion?
Based on an overall assessment of its quality, value and momentum Artivion is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Artivion share price forecast for 2025?
The analyst consensus target price for shares in Artivion is $32.33. That is 35.61% above the last closing price of $23.84.
Analysts covering Artivion currently have a consensus Earnings Per Share (EPS) forecast of $0.02 for the next financial year.
Find out moreWhat is the trend in the Artivion share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Artivion. Over the past six months, its share price has underperformed the S&P500 Index by -5.07%.
As of the last closing price of $23.84, shares in Artivion were trading -11.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Artivion PE Ratio?
The Artivion PE ratio based on its reported earnings over the past 12 months is 171.07. The shares last closed at $23.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Artivion?
Artivion's management team is headed by:
- James Mackin - CHM
- D. Ashley Lee - CFO
- Jean Holloway - SVP
- John Davis - SVP
- Amy Horton - CAO
- Dennis Maier - VOP
- Matthew Getz - VPR
- F. Peter Barthold - VPR
- Scott Capps - VPR
- Thomas Ackerman - IND
- Daniel Bevevino - IND
- Marna Borgstrom - IND
- James Bullock - IND
- Jeffrey Burbank - IND
- Jon Salveson - IND
- Anthony Semedo - IND